FAK-IN-28 is an orally active FAK inhibitor with an IC50 of 0.4 nM. It exhibits both antiproliferative and antimetastatic effects. FAK-IN-28 induces apoptosis by triggering caspase-3-dependent pathways through increased ROS levels. This compound effectively inhibits tumor growth without causing weight loss or hepatorenal toxicity. FAK-IN-28 is suitable for research on FAK-driven malignancies, including colon cancer, cervical cancer, triple-negative breast cancer, and melanoma.
Target-Kategorie:
ROS|||FAK|||Apoptosis|||Caspase
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
